SAN

78.85

-1.73%↓

UCB

236.4

-0.42%↓

SHL.DE

35.58

+0.45%↑

ARGX

676.4

+1.47%↑

VIE

35.58

-0.03%↓

SAN

78.85

-1.73%↓

UCB

236.4

-0.42%↓

SHL.DE

35.58

+0.45%↑

ARGX

676.4

+1.47%↑

VIE

35.58

-0.03%↓

SAN

78.85

-1.73%↓

UCB

236.4

-0.42%↓

SHL.DE

35.58

+0.45%↑

ARGX

676.4

+1.47%↑

VIE

35.58

-0.03%↓

SAN

78.85

-1.73%↓

UCB

236.4

-0.42%↓

SHL.DE

35.58

+0.45%↑

ARGX

676.4

+1.47%↑

VIE

35.58

-0.03%↓

SAN

78.85

-1.73%↓

UCB

236.4

-0.42%↓

SHL.DE

35.58

+0.45%↑

ARGX

676.4

+1.47%↑

VIE

35.58

-0.03%↓

Home・Akcijų sąrašas・Vetoquinol SA

Vetoquinol SA

Uždarymo kaina

SektoriusSveikatos priežiūra

79.9 -1.6

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

79.9

Max

81.3

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M
Pardavimai	10M 268M
P/E Sektoriaus vid.	16.471 60.328
Dividendų pajamingumas	1.16
Pelno marža	9.734
Darbuotojai	2,497
EBITDA	252M 301M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+34.31% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.16% 2.24%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	59M 994M
Ankstesnė atidarymo kaina	81.5
Ankstesnė uždarymo kaina	79.9

Naujienos nuotaikos

By Acuity

50%

141 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

72.6 / 75.1 Palaikymas ir pasipriešinimas

Vetoquinol SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-26 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

2026-04-26 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Major Central Bank -2-

2026-04-24 19:19; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Group Rejects EQT's Revised Offer

2026-04-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Gains -- Market Talk

2026-04-26 23:44; UTC

Uždarbis

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

2026-04-26 23:44; UTC

Uždarbis

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

2026-04-26 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls Amid Dollar's Strength -- Market Talk

2026-04-26 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

2026-04-26 05:12; UTC

Uždarbis

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

2026-04-24 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Scoring the Cook Era -- Barrons.com

2026-04-24 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-24 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:09; UTC

Uždarbis

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026-04-24 19:48; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026-04-24 19:22; UTC

Uždarbis

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026-04-24 19:06; UTC

Uždarbis

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026-04-24 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026-04-24 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026-04-24 18:28; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Rejects Revised EQT Offer

2026-04-24 18:12; UTC

Rinkos pokalbiai

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026-04-24 18:06; UTC

Rinkos pokalbiai

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026-04-24 17:42; UTC

Uždarbis

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026-04-24 17:28; UTC

Uždarbis

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Vetoquinol SA Prognozė

Kainos tikslas

By TipRanks

34.31% į viršų

12 mėnesių prognozė

Vidutinis 110 EUR 34.31%

Aukščiausias 110 EUR

Žemiausias 110 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vetoquinol SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Vetoquinol SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

72.6 / 75.1Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

141 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.